Self-Measured Blood Pressure Monitoring at Home: A Joint Policy Statement From the American Heart Association and American Medical Association. 2020

Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and

The diagnosis and management of hypertension, a common cardiovascular risk factor among the general population, have been based primarily on the measurement of blood pressure (BP) in the office. BP may differ considerably when measured in the office and when measured outside of the office setting, and higher out-of-office BP is associated with increased cardiovascular risk independent of office BP. Self-measured BP monitoring, the measurement of BP by an individual outside of the office at home, is a validated approach for out-of-office BP measurement. Several national and international hypertension guidelines endorse self-measured BP monitoring. Indications include the diagnosis of white-coat hypertension and masked hypertension and the identification of white-coat effect and masked uncontrolled hypertension. Other indications include confirming the diagnosis of resistant hypertension and detecting morning hypertension. Validated self-measured BP monitoring devices that use the oscillometric method are preferred, and a standardized BP measurement and monitoring protocol should be followed. Evidence from meta-analyses of randomized trials indicates that self-measured BP monitoring is associated with a reduction in BP and improved BP control, and the benefits of self-measured BP monitoring are greatest when done along with cointerventions. The addition of self-measured BP monitoring to office BP monitoring is cost-effective compared with office BP monitoring alone or usual care among individuals with high office BP. The use of self-measured BP monitoring is commonly reported by both individuals and providers. Therefore, self-measured BP monitoring has high potential for improving the diagnosis and management of hypertension in the United States. Randomized controlled trials examining the impact of self-measured BP monitoring on cardiovascular outcomes are needed. To adequately address barriers to the implementation of self-measured BP monitoring, financial investment is needed in the following areas: improving education and training of individuals and providers, building health information technology capacity, incorporating self-measured BP readings into clinical performance measures, supporting cointerventions, and enhancing reimbursement.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006291 Health Policy Decisions, usually developed by government policymakers, for determining present and future objectives pertaining to the health care system. Health Care Policies,Health Policies,Healthcare Policy,National Health Policy,Care Policies, Health,Health Care Policy,Health Policy, National,Healthcare Policies,National Health Policies,Policies, Health,Policies, Health Care,Policies, Healthcare,Policy, Health,Policy, Health Care,Policy, Healthcare
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000572 American Heart Association A voluntary organization concerned with the prevention and treatment of heart and vascular diseases. American Heart Associations,Association, American Heart,Associations, American Heart,Heart Association, American,Heart Associations, American
D000574 American Medical Association Professional society representing the field of medicine. AMA - American Medical Association,AMA American Medical Association,Association, American Medical,Medical Association, American
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D017410 Practice Guidelines as Topic Works about directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. Clinical Guidelines as Topic,Best Practices,Best Practice

Related Publications

Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
July 2020, Circulation,
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
September 1985, Diabetes,
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
January 2008, The Journal of cardiovascular nursing,
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
July 2008, Hypertension (Dallas, Tex. : 1979),
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
May 2014, Hypertension (Dallas, Tex. : 1979),
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
July 2008, Hypertension (Dallas, Tex. : 1979),
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
January 2008, Journal of the American Society of Hypertension : JASH,
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
June 2008, Journal of clinical hypertension (Greenwich, Conn.),
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
October 2014, Circulation,
Daichi Shimbo, and Nancy T Artinian, and Jan N Basile, and Lawrence R Krakoff, and Karen L Margolis, and Michael K Rakotz, and Gregory Wozniak, and
July 2022, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!